In conclusion, our results firstly suggest that MSTN-ASO therapy can alleviate CKD-induced muscle atrophy by downregulating MSTN, Atrogin-1, and MuRF-1, key muscle degradation mediators, and by increasing the muscle CSA, mass, strength, and function. The gene discussed is FBXO32; the disease is chronic kidney disease.